¸ÂÃãÇü ÀÇ·á¿¡¼­ AIÀÇ ±âȸ
AI Opportunities in Personalised Medicine
»óǰÄÚµå : 1759018
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 8,000 £Ü 11,013,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

º» º¸°í¼­´Â °³ÀÎÈ­µÈ ÀÇ·á¿¡¼­ AIÀÇ ±âȸ¸¦ Á¶»çÇϰí, AI¸¦ Ȱ¿ëÇÑ ±â¼úÀÌ ¾î¶»°Ô ÀǾàǰ °³¹ßÀÇ À§ÇèÀ» ÁÙÀ̰í, ȯÀÚ °èÃþÈ­¸¦ °­È­Çϸç, ÀÇ·áÀÇ °³ÀÎÈ­¸¦ ÃËÁøÇϰí ÀÖ´ÂÁö ÀÚ¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÇ·á °³ÀÎÈ­¸¦ À§ÇØ AI¸¦ Ȱ¿ëÇÑ ½ÇÁ¦ ÀÌ¿ë »ç·Ê¿Í ±³ÈÆÀ» ¼Ò°³Çß½À´Ï´Ù.

ÁÖ¿ä ³»¿ë

ÁÖ¿ä ±â¾÷

  • AbbVie
  • AI Proteins
  • Aitia
  • AstralBio
  • AstraZeneca
  • Bayer
  • BigHat Biosciences
  • Boehringer Ingelheim
  • Brightseed
  • Bristol Myers Squibb
  • Carebot
  • Caris Life Sciences
  • Certis Oncology Solutions
  • Charles River Laboratories
  • Click Therapeutics
  • ConcertAI
  • Dyno Therapeutics
  • Eko Health
  • Eli Lilly
  • Formation Bio
  • Genentech
  • Genesis Therapeutics
  • Gilead
  • Google
  • Google DeepMind
  • GS
  • K Haleon
  • Harbour BioMed
  • Iambic Therapeutics
  • iBio
  • Immunai
  • Incyte
  • Inimmune
  • Insilico Medicine
  • invoX Pharma
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck & Co.
  • Microsoft
  • Moderna
  • Novartis
  • Novo Nordisk
  • Nvidia
  • OpenAI
  • Optellum
  • Otsuka
  • Owkin
  • Paige.AI
  • Path AI
  • Pathos
  • Pfizer
  • Qureight
  • Rad AI
  • Rein Therapeutics
  • Roche
  • »ç³ëÇÇ
  • Servier
  • Snowflake
  • Takeda
  • Tempus
  • Tenacia Biotechnology
  • Tevogen Bio
  • Therasid Bioscience
  • Valo Health
  • Variational AI
LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

This report explores the transformative role of artificial intelligence in personalised medicine, focusing on its application in drug discovery and clinical decision making. It provides an in-depth analysis of how AI-enabled technologies are mitigating risks in drug development, enhancing patient stratification and facilitating the personalisation of care. The report also highlights real-world use cases and lessons learned from deploying AI to personalise medical care, offering a comprehensive overview for biopharma professionals looking to navigate the evolving landscape of AI-driven healthcare solutions.

Gain insights into the significant impact of AI on the development of personalised therapies, the key challenges in integrating AI with human capabilities and the future opportunities for biopharma to leverage AI in improving market access and reimbursement strategies.

Key Questions Answered:

Key Companies:

  • AbbVie
  • AI Proteins
  • Aitia
  • AstralBio
  • AstraZeneca
  • Bayer
  • BigHat Biosciences
  • Boehringer Ingelheim
  • Brightseed
  • Bristol Myers Squibb
  • Carebot
  • Caris Life Sciences
  • Certis Oncology Solutions
  • Charles River Laboratories
  • Click Therapeutics
  • ConcertAI
  • Dyno Therapeutics
  • Eko Health
  • Eli Lilly
  • Formation Bio
  • Genentech
  • Genesis Therapeutics
  • Gilead
  • Google
  • Google DeepMind
  • GS
  • K Haleon
  • Harbour BioMed
  • Iambic Therapeutics
  • iBio
  • Immunai
  • Incyte
  • Inimmune
  • Insilico Medicine
  • invoX Pharma
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck & Co.
  • Microsoft
  • Moderna
  • Novartis
  • Novo Nordisk
  • Nvidia
  • OpenAI
  • Optellum
  • Otsuka
  • Owkin
  • Paige.AI
  • Path AI
  • Pathos
  • Pfizer
  • Qureight
  • Rad AI
  • Rein Therapeutics
  • Roche
  • Sanofi
  • Servier
  • Snowflake
  • Takeda
  • Tempus
  • Tenacia Biotechnology
  • Tevogen Bio
  • Therasid Bioscience
  • Valo Health
  • Variational AI

Partial List of Participating Experts:

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â